HHEX and prostate cancer: We previously produced conformation-specific antibodies that recognise preferentially either hypophosphorylated PRH (hypo-PRH) or hyper-phosphorylated PRH (pPRH) and we used these antibodies to show that the inhibition of CK2 in leukaemic cells with specific inhibitors leads to loss of detection of pPRH.13 To examine the expression and phosphorylation status of PRH in prostate epithelial cells we made use of a normal immortalised prostate epithelial cell line (PNT2-C2 cells17, 18) and two well-characterised prostate cancer cell lines (DU145 and PC3 cells).